在歐盟國家中有40%的個體都遭受著非酒精性脂肪性肝炎的痛苦，在當前富裕社會下這種疾病的流行率越來越高，其也是個體糖尿病和體重過度增加的直接結果，當前研究者并不可能預測這種疾病的未來發(fā)展情況，而其直接的結果似乎只能是肝硬化和肝癌，此外其也會增加個體患心臟病發(fā)作及腎臟損傷的風險，未來研究者或將利用不同生物標志物的風險評分來對該疾病進行預測。

    來自維也納醫(yī)科大學的研究者表示，我們開發(fā)的這種風險評分在臨床試驗中已經(jīng)得到了證實，研究者中我們想去尋找臨床使用的生物標志物，來促進我們對非酒精性脂肪性肝炎患者的非侵入性風險評估，而并不僅僅是進行肝臟活檢；最初的研究結果非常有前途。

    研究者Trauner表示，我們假定存在一種生物標志物的混合物，其來自于對風險評分所解析的結果，這種混合物就包括來自血液、腸道微生物組及遺傳學上的生物標志物；通過對生物標志物進行分析，研究者就可以更好地評估非酒精性脂肪肝在未來的發(fā)展情況，從而幫助我們更好地回答一系列問題，比如如果脂肪肝持續(xù)存在的話，為何現(xiàn)在非酒精性脂肪肝比此前發(fā)展地更為迅猛？

    同時在個體化醫(yī)療的范圍內研究人員將會很容易及時采取正確的治療手段；目前大約40%的歐洲人口備受非酒精性脂肪肝的影響，該疾病最終會引發(fā)肝炎、肝硬化甚至肝癌；非酒精性脂肪肝和糖尿病、過重及代謝性綜合征強烈相關，同時也和機體自身的遺傳因素及腸道微生物組直接相關；后期研究者將通過更為深入的研究來揭示引發(fā)非酒精性脂肪肝的分子機制，同時為開發(fā)新型療法治療該疾病也提供了新的思路和線索。

    推薦的新聞閱讀：

    This Risk Score is being developed and validated at the Clinical Department for Gastroenterology and Hepatology at the MedUni Wien in cooperation with the University Clinics for Surgery and Radiology / Nuclear Medicine and partners from the industry. The project is also integrated into the new Austrian centre of competence “CBmed,” which the MedUni Wien is involved in to 20 percent.

    The objective is to find biomarkers for clinical use in order to facilitate a non-invasive evaluation of the risk, i.e. without a liver biopsy. The initial results are extremely promising, according to Michael Trauner, Head of the Department for Gastroenterology and Hepatology （University Clinic for Internal Medicine III）： “We can assume that, in the end, there will be a mixture of biomarkers from which a Risk Score can be compiled.” This mix will include markers from blood, from the microbiome in the intestine and genetic markers, and markers from imaging processes including the latest applications of Positron-Emission-Tomography （PET）。

    “As a result, we will be able to estimate the course of the disease better in future, and therefore will be better able to answer the question of 'how will it develop' than before, if a liver steatohepatitis already exists,” says Trauner. At the same time, within the scope of personalised medicine, it is then also easier to take the correct therapeutic steps in due time.

    Around 40 percent of the population are already affected by non-alcoholic steatohepatitis, which can lead to hepatitis （fatty liver hepatitis） and cirrhosis and cancer of the liver……